TrialJournal for immunotherapy of cancer2023

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.

Matthew H G Katz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.